Project Grant R44DK146594
Award Date 8/21/26
Completion Date 4/30/29
Dollars Obligated $307K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- Cobio Diagnostics Inc. received a $256,000 Project Grant award from the National Science Foundation on April 1, 2021 to support work concluding on March 31, 2022. The grant was awarded under the NSF's Engineering program (CFDA 47.041), which aims to improve quality of life and economic strength through engineering research and education. Specifically, the grant funds Cobio Diagnostics' "SBIR PHASE I: PHAGE-AMPLIFIED IDENTIFICATION AND ANTIMICROBIAL SUSCEPTIBILITY TEST" project. This...
- The National Institute of Allergy and Infectious Diseases awarded the University of Texas at Dallas $465,664 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for development and validation of USENSE, an electrochemical point-of-care diagnostic platform for urinary tract infections. USENSE is a portable biosensor designed to quantitate three urinary analytes within 5–10 minutes and apply machine learning diagnostic algorithms to output UTI risk...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Kscube, LLC $315,335 on August 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a real-time, non-invasive urinary oxygen monitoring system for acute kidney injury prevention. The recipient will advance development of a novel continuous kidney-stress monitor for use during surgery and in intensive care units. The technology provides real-time detection of...
- The Centers for Disease Control and Prevention awarded $613,744 to SKM Instruments, Inc. on September 30, 2025, under the Prevention of Disease, Disability, and Death by Infectious Diseases program (CFDA 93.084) to develop an ultra-rapid optical platform for antimicrobial susceptibility testing of pulmonary non-tuberculous mycobacterial infections. Performance occurs in Wyoming, with a period of performance extending through May 31, 2026. The project grant supports the development of...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $795,317 to the Research Institute At Nationwide Children's Hospital on August 19, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the roles of RNase3, RNase6, and ribonuclease inhibitor in bacterial urinary tract infection. The research uses engineered transgenic mice to determine how RNase3 and RNase6, phagocyte-derived antimicrobial peptides in the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Research Foundation for the State University of New York $2,401,176 on September 9, 2025, to support research investigating polymicrobial interactions and within-host bacterial adaptation in catheter-associated urinary tract infections (CAUTI). The research examines how three species — Enterococcus faecalis, Proteus mirabilis, and Escherichia coli — interact to enhance biofilm formation on urinary catheters and...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded In Vivo Microsystems Technologies, LLC $3,067,867 on September 19, 2025, for a Phase 2 Small Business Innovation Research project under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). IVMT will conduct a Phase 2 multi-center in-vivo study of a near-infrared fluorescently-labeled peptide heterodimer targeting EGFR and ERBB2 for detection of biliary intra-epithelial neoplasia. The...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Pupil Bio, Inc. $1,015,056 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop an early detection test for Type 1 Diabetes using next-generation sequencing analysis of B cell-specific methylation patterns in cell-free DNA. Pupil Bio will refine marker selection to identify methylation patterns ultra-specific to pancreatic islet B cells, building...
- The National Institute of Allergy and Infectious Diseases awarded Catholic University of America $596,250 on May 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to prototype a rapid antibiotic susceptibility testing platform using multiplex static gradients. The project aims to develop a microfluidic device that identifies effective antibiotics within 30 minutes for acute bacterial infections such as sepsis, urinary tract infections, and bloodstream...
- The National Institute of Diabetes and Digestive and Kidney Diseases, part of the Department of Health and Human Services, awarded Silq Technologies Corporation $320,965 on August 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). Silq will develop a zwitterion-treated ureteral stent designed to reduce device-related complications in patients with ureteral obstructions. The work encompasses three aims: developing the zwitterion-treated...